

Special Issue

Parasitic Infections: Therapy for Host Immunity and Vaccination—2nd Edition

Message from the Guest Editors

Over the past few decades, there has been extensive research into pharmaceutical alternatives to deal with adverse effects caused by parasites in humans and animals. This is mainly due to the development of resistance to antiparasitic drugs and the ecological problems associated with pharmacological residues in the environment and animal products for human consumption. However, there are still very few tools available to address more complex parasitic groups, such as helminths and arthropods. Many alternative strategies focus on enhancing the immune response of hosts to reduce parasite development. However, the results have not always been as expected, possibly due to the complexity of host–parasite interactions and environmental involvement. We welcome original manuscripts, reviews, brief communications, meta-analyses, and other types of articles reporting vaccination and therapy trials against parasites for a Special Issue in *Vaccines*. We encourage the analysis of immune mechanisms against parasites and the relationship between protection and antiparasitic control strategies.

Guest Editors

Prof. Dr. José Manuel Molina Caballero

Department of Animal Pathology, Faculty of Veterinary Medicine,
University of Las Palmas de Gran Canaria, Gran Canaria, Spain

Dr. Antonio Ruiz Reyes

Department of Animal Pathology, Faculty of Veterinary Medicine,
University of Las Palmas de Gran Canaria, Gran Canaria, Spain

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/252638

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).